On September 21, 2010, the U.S. Food and Drug Administration ("FDA") approved Fingolimod capsules (Gilenya, Novartis International AG) for reducing the frequency of relapses and delaying the accumulation of disabling symptoms in relapsing forms of Multiple Sclerosis ("MS"). This is the first oral disease-modifying therapy for the treatment of MS. According to Novartis, the drug will be available for prescription in the coming weeks.
Thanks to the National MS Society website for releasing this information.
For assistance with your Long Term Disability claim, ERISA Disability benefit claim, Social Security Disability claim, or Veterans Disability compensation or pension claim, call Disability Lawyer John Tucker at (866) 282-5260.
1 comment:
I hope this works..
Post a Comment